GlassScriptPhysician profile
Brion V Randolph
NPI 1316148547
$162,148.98
in general payments reported to CMS, 2019-2025
39 companies · $1,324 in 2025
The $1,324 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102K · 2020: $14K · 2021: $6,544 · 2022: $19K · 2023: $702 · 2024: $18K · 2025: $1,324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,155 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,278 · Food and Beverage: $3,501 · Travel and Lodging: $2,814 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,155.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,278.00 |
| Food and Beverage | $3,501.17 |
| Travel and Lodging | $2,814.31 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $153.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $119,529.00 | 2019-2025 | Breyanzi, Onureg, Reblozyl |
| E.R. Squibb & Sons, L.L.C. | $27,037.02 | 2022-2025 | Breyanzi |
| Vertex Pharmaceuticals Incorporated | $8,102.94 | 2024 | |
| Agios Pharmaceuticals, INC. | $4,301.21 | 2019-2024 | Pyrukynd |
| Astellas Pharma US INC | $287.72 | 2020-2025 | Cresemba, Vyloy, Xospata |
| Janssen Biotech, INC. | $254.23 | 2022-2025 | Carvykti, Talvey, Darzalex |
| Kite Pharma, INC. | $226.24 | 2021-2025 | Yescarta |
| Daiichi Sankyo INC. | $208.06 | 2023-2025 | Vanflyta |
| Sanofi-Aventis U.S. LLC | $201.55 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $171.01 | 2025 | |
| Pfizer INC. | $145.65 | 2023-2025 | |
| Kadmon Pharmaceuticals LLC | $140.65 | 2021 | |
| Jazz Pharmaceuticals INC. | $139.35 | 2022-2024 | |
| Adaptive Biotechnologies Corporation | $136.26 | 2022-2025 | Clonoseq |
| Glaxosmithkline, LLC. | $117.76 | 2023-2025 | Ojjaara |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $108.31 | 2022-2025 | Ninlaro |
| Genzyme Corporation | $95.88 | 2024-2025 | |
| Servier Pharmaceuticals LLC | $92.58 | 2022-2025 | |
| Adc Therapeutics America, INC. | $91.59 | 2022 | |
| Cti Biopharma Corp. | $77.45 | 2022-2023 | Vonjo |
| Beigene USA, INC. | $68.38 | 2022-2024 | Brukinsa |
| Legend Biotech USA INC. | $61.57 | 2024-2025 | Carvykti |
| Iovance Biotherapeutics, INC. | $61.38 | 2025 | Amtagvi |
| Rigel Pharmaceuticals, INC. | $57.07 | 2023-2024 | Rezlidhia, Tavalisse |
| Merck Sharp & Dohme LLC | $56.42 | 2024-2025 | Reblozyl |
| Taiho Oncology, INC. | $55.35 | 2023-2025 | |
| Lilly USA, LLC | $43.19 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Eisai INC. | $34.90 | 2019 | |
| Secura Bio, INC. | $32.61 | 2024-2025 | Copiktra |
| Novartis Pharmaceuticals Corporation | $29.60 | 2024-2025 | |
| Amgen INC. | $28.74 | 2022 | |
| Azurity Pharmaceuticals, INC. | $22.00 | 2025 | Danziten |
| Genmab U.S., INC. | $21.24 | 2025 | Epkinly |
| Abbvie INC. | $20.59 | 2024 | |
| Kyowa Kirin, INC. | $20.52 | 2025 | |
| Incyte Corporation | $18.54 | 2025 | Jakafi, Niktimvo |
| Pharmaessentia USA Corporation | $18.53 | 2024 | Besremi |
| Apellis Pharmaceuticals, INC. | $18.04 | 2022 | |
| Emd Serono, INC. | $15.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brion Randolph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.